Pfizer’s Kristin Peck gains business development role
pharmafile | March 1, 2010 | Appointment | Sales and Marketing | Pfizer, appointment, sales and marketing
Kristin Peck has been appointed senior vice president, worldwide business development, strategy and innovation at Pfizer.
She succeeds William Ringo in the role, which will see her assume responsibility for business development activities and ensuring their alignment with Pfizer’s strategic objectives.
“Kristin has already been playing a leadership role in strategic planning for the company. Her knowledge, expertise and energy make her an excellent choice for this leadership position,” Pfizer’s chairman and chief executive Jeff Kindler said.
“Kristin will work closely with me and other Pfizer executives to advance our business development goals effectively and with an efficient use of our owners’ capital.”
Peck joined Pfizer in 2004 in the company’s strategic planning organisation. Prior to Pfizer, she was a principal with the Boston Consulting Group, focusing on strategy and merger-related issues in the pharmaceutical and financial services industries, and worked in real estate financial services and private equity at Prudential and The O’Connor Group.
At Pfizer she most recently played a leadership role in the integration of Wyeth’s global operations, while serving as senior vice president of worldwide strategy and innovation.
Meanwhile Ringo, her predecessor in her new role, will retire from the company with effect from 30 April.
“Bill has accomplished a great deal in positioning Pfizer for future success,” said Kindler.
“He has helped diversify Pfizer’s portfolio through our acquisition of Wyeth; worked to create a new world-leading, specialist HIV company, called ViiV Healthcare, through our joint venture with GlaxoSmithKline; and played a leadership role in securing rights to novel, promising compounds.”
“He also connected the company more closely with the expanding opportunities in biotechnology,” Kindler added.
Ringo joined Pfizer in April 2008, after retiring from Eli Lilly & Company, where over his 28-year tenure he held a number of senior positions.
“It has been a real pleasure to be part of Pfizer’s Executive Leadership Team,” Ringo said. “Based on my four decades of experience in the industry, I truly believe the future for Pfizer is extremely bright, as our colleagues provide quality medicines to patients around the world,” he added.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
